SIG
ITCI

Sargent Investment Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Sargent Investment Group’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,923
Closed -$221K – 202
2021
Q3 		$221K Buy
5,923
+850
+17% +$29.5K 0.05% 174
2021
Q2 		$207K Buy
+5,073
New +$188K 0.05% 187

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Sargent Investment Group's ITCI Position: Q4 2021 in Review

Sargent Investment Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2021, closing a stake of 5,923 shares — an estimated $221K sold.

Sargent Investment Group first reported a position in ITCI in Q2 2021 and held it in 2 quarters. The position peaked at $221K in Q3 2021. 208 funds tracked by Wall St. Rank hold ITCI as of Q4 2021.

  • Sargent Investment Group reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2021 after selling out during the quarter.
  • Sargent Investment Group sold 5,923 Intra-Cellular Therapies Inc. shares in Q4 2021, an estimated $221K.
  • Sargent Investment Group first reported a position in Intra-Cellular Therapies Inc. in Q2 2021 and held it in 2 quarters.
  • Sargent Investment Group's Intra-Cellular Therapies Inc. position peaked at $221K in Q3 2021.
  • 208 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2021.

Based on Sargent Investment Group's 13F filing for Q4 2021, filed 11 Feb 2022.